Lunai Bioworks Inc. (NASDAQ: LNAI)

Lunai Bioworks Inc. operates through three subsidiaries: Renovaro Biosciences Renovaro Cube and BioSymetrics. Renovaro Biosciences is dedicated to creating allogeneic cell and gene therapeutic vaccines that train the immune system to recognize and eliminate cancer cells with the goal of achieving long term remission. Its lead programs include RENB DC11 targeting pancreatic tumors and RENB DC20 focusing on triple negative breast cancer using dendritic cell platforms. Renovaro Cube provides an artificial intelligence driven platform that processes multi omic data from sources such as genomics transcriptomics epigenomics and proteomics to enable early cancer detection recurrence monitoring treatment response prediction and drug discovery support. BioSymetrics delivers biomedical artificial intelligence solutions that integrate imaging genomics electronic health records and other real world evidence to generate insights for target identification predictive modeling clinical trial optimization and experimental screening of novel therapeutics.

The company anticipates revenue from the sale of its therapeutic products once they obtain regulatory approval and achieve market adoption. Renovaro Cube expects to generate income through the sale of diagnostic test kits licensing of its AI driven platform to hospitals research centers and pharmaceutical companies and fees from its service laboratories that perform liquid biopsy analysis. BioSymetrics plans to earn revenue by offering its biomedical AI platform as a service to pharmaceutical partners for drug discovery projects and by providing data analysis and biomarker discovery support under collaborative agreements. Partnerships with academic institutions and clinical sites are also expected to contribute to income through sponsored research and development agreements.

The company operates through the following segments: Renovaro Biosciences Renovaro Cube and BioSymetrics.

• Renovaro Biosciences: This segment develops allogeneic cell and gene therapeutic vaccines such as RENB DC11 and RENB DC20 that are designed to induce durable immune responses against solid tumors with the aim of achieving long term remission in patients with pancreatic and triple negative breast cancer.

• Renovaro Cube: This segment provides an AI driven platform that analyzes multi omic data to enable early cancer detection recurrence prediction treatment response tracking and drug discovery support for healthcare providers researchers and pharmaceutical companies.

• BioSymetrics: This segment delivers biomedical artificial intelligence tools that integrate genomics imaging electronic health records and other real world evidence to uncover clinically actionable insights for target identification predictive modeling clinical trial optimization and experimental screening of novel drug targets.

In the field of allogeneic cell therapies Renovaro Biosciences competes with companies developing off the shelf dendritic cell vaccines and personalized CAR T cell treatments but it distinguishes itself by focusing on dendritic cell based vaccines that can be manufactured in large batches and stored for immediate use. In the AI driven diagnostics market Renovaro Cube faces competition from firms such as Grail Freenome and Owkin yet it offers a unique explainable AI system that integrates multi omic data for differential diagnosis and provides transparent insights into the biological markers driving its predictions. BioSymetrics operates alongside companies like Recursion Pharma and insitro but provides a distinctive combination of contingent AI technology and a phenograph knowledge graph that enables multi modal analysis of complex biomedical datasets for neurotherapeutic and oncological research. Overall Lunai Bioworks Inc. leverages its integrated pipeline of therapeutic development AI driven diagnostics and multi omic analytics to deliver a differentiated approach that addresses both early detection and long term treatment needs in oncology and related disease areas.

The company serves hospitals clinics diagnostic laboratories insurance companies pharmaceutical biotech companies research centers physicians and individual patients seeking advanced cancer diagnostics and therapeutics. While specific customer names are not disclosed in the filing the target market includes academic medical centers reference laboratories and pharmaceutical partners engaged in collaborative validation studies and service agreements. Renovaro Cube also aims to work with public health agencies and screening programs that require early detection tools for population based cancer monitoring. BioSymetrics collaborates with drug developers to provide AI driven insights that assist in lead optimization safety assessment and clinical trial design.